Patterns of Belatacept Use and Risk of Post-transplant Lymphoproliferative Disorder in US Kidney Transplant Recipients: An Analysis of the Organ Procurement and Transplantation Network Database

Overview

Journal PLoS One

Date 2025 Jan 10

PMID 39792912

Authors

Wida S Cherikh

Tzuyung Douglas Kou

Julia Foutz

Timothy J Baker

Andres Gomez-Caminero

Affiliations

Soon will be listed here.

Abstract

Background: Belatacept is approved for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients and is associated with a risk of post-transplant lymphoproliferative disorder (PTLD).

Methods: Data from the Organ Procurement and Transplantation Network were used to examine patterns of belatacept use, describe patient characteristics, and estimate risk of PTLD in EBV-seropositive, kidney-only transplant recipients receiving belatacept- or calcineurin inhibitor (CNI)-based immunosuppression as part of US Food and Drug Administration-mandated safety monitoring.

Results: During the study period (June 15, 2011-June 14, 2016), 94.9% (1631/1719) of belatacept-treated and 89.7% (59,992/66,905) of CNI-treated patients with known EBV serostatus were EBV seropositive. Among EBV-seropositive patients, 50.2% (belatacept) and 56.8% (CNI) received a standard criteria donor kidney, 59.5% and 18.7% received basiliximab induction, and 22.9% and 50.8% received antithymocyte globulin induction. PTLD developed in nine belatacept-treated patients (two with central nervous system [CNS] involvement) and 225 CNI-treated patients (nine with CNS involvement). Four and 81 patients, respectively, died due to PTLD. Kaplan-Meier analysis did not show a significant between-group difference in PTLD estimated incidence rates within 5 years (0.70% versus 0.48%, respectively; p = 0.18). Additionally, estimated PTLD incidence was not significantly different between treatment groups in a propensity score matched cohort.

Conclusions: The majority of adult kidney-only transplant recipients treated with belatacept in routine clinical practice are EBV seropositive. In this study, the risk of PTLD in these patients, while higher than for CNI-based immunosuppression, remained low after adjusting for differences in patient characteristics.

Trial Registration: These studies are registered at ClinicalTrials.gov: NCT01670058 and NCT01656343.

References

Dharnidharka V, Tejani A, Ho P, Harmon W . Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. 2002; 2(10):993-8. DOI: 10.1034/j.1600-6143.2002.21019.x. View

Al-Mansour Z, Nelson B, Evens A . Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013; 8(3):173-83. PMC: 4831913. DOI: 10.1007/s11899-013-0162-5. View

Velvet A, Bhutani S, Papachristos S, Dwivedi R, Picton M, Augustine T . A single-center experience of post-transplant lymphomas involving the central nervous system with a review of current literature. Oncotarget. 2019; 10(4):437-448. PMC: 6355190. DOI: 10.18632/oncotarget.26522. View

Durrbach A, Pestana J, Florman S, Del Carmen Rial M, Rostaing L, Kuypers D . Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study. Am J Transplant. 2016; 16(11):3192-3201. PMC: 5516151. DOI: 10.1111/ajt.13830. View

Maksten E, Vase M, Kampmann J, DAmore F, Moller M, Strandhave C . Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study. Transpl Int. 2016; 29(4):483-93. DOI: 10.1111/tri.12744. View

Durrbach A, Pestana J, Pearson T, Vincenti F, Garcia V, Campistol J . A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010; 10(3):547-57. DOI: 10.1111/j.1600-6143.2010.03016.x. View

Azzi J, Sayegh M, Mallat S . Calcineurin inhibitors: 40 years later, can't live without . J Immunol. 2013; 191(12):5785-91. DOI: 10.4049/jimmunol.1390055. View

Corrigan-Curay J, Sacks L, Woodcock J . Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. JAMA. 2018; 320(9):867-868. DOI: 10.1001/jama.2018.10136. View

Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J . Summary of the US FDA approval of belatacept. Am J Transplant. 2012; 12(3):554-62. DOI: 10.1111/j.1600-6143.2011.03976.x. View

10.

Lamberti M, Kubick W, Awatin J, McCormick J, Carroll J, Getz K . The Use of Real-World Evidence and Data in Clinical Research and Postapproval Safety Studies. Ther Innov Regul Sci. 2018; 52(6):778-783. DOI: 10.1177/2168479018764662. View

11.

Yoon J, Lee S, Kim H, Lee J, Min W, Chung B . Comparative analysis of post-transplant lymphoproliferative disorder after kidney transplantation versus hematopoietic stem cell transplantation. Transpl Int. 2014; 27(7):721-32. DOI: 10.1111/tri.12328. View

12.

Racusen L, Solez K, Colvin R, Bonsib S, Castro M, CAVALLO T . The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999; 55(2):713-23. DOI: 10.1046/j.1523-1755.1999.00299.x. View

13.

Masson P, Henderson L, Chapman J, Craig J, Webster A . Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014; (11):CD010699. PMC: 6486198. DOI: 10.1002/14651858.CD010699.pub2. View

14.

Bestard O, Campistol J, Morales J, Sanchez-Fructuoso A, Cabello M, Cabello V . Advances in immunosuppression for kidney transplantation: new strategies for preserving kidney function and reducing cardiovascular risk. Nefrologia. 2012; 32(3):374-84. DOI: 10.3265/Nefrologia.pre2012.Jan.11176. View

15.

Gwon J, Kim Y, Han D . Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000. Asian J Surg. 2018; 42(4):551-556. DOI: 10.1016/j.asjsur.2018.09.002. View

16.

Miller L . Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002; 2(9):807-18. DOI: 10.1034/j.1600-6143.2002.20902.x. View

17.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L . Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016; 374(4):333-43. DOI: 10.1056/NEJMoa1506027. View

18.

Malvezzi P, Rostaing L . The safety of calcineurin inhibitors for kidney-transplant patients. Expert Opin Drug Saf. 2015; 14(10):1531-46. DOI: 10.1517/14740338.2015.1083974. View

19.

Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P . A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10(3):535-46. DOI: 10.1111/j.1600-6143.2009.03005.x. View

20.

Imamura R, Nakazawa S, Yamanaka K, Kakuta Y, Tsutahara K, Taniguchi A . Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long-term multicenter cohort study. Cancer Med. 2020; 10(7):2205-2215. PMC: 7982608. DOI: 10.1002/cam4.3636. View